Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model

Autor: Gutiérrez Calderón, Vanesa, Cantero González, Alexandra, Gálvez Carvajal, Laura, Aguilar Lizarralde, Yolanda, Rueda Domínguez, Antonio
Přispěvatelé: [Gutiérrez Calderón,V: Cantero González,A, Gálvez Carvajal,L] Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. [Aguilar Lizarralde,Y] Servicio de Cirugía Maxilofacial, Hospital Regional Universitario, Málaga, Spain. [Rueda Domínguez,A] Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Diseases::Pathological Conditions
Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]
Neoplasias de cabeza y cuello
Diseases::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms [Medical Subject Headings]
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy [Medical Subject Headings]
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]
Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]
Terapia neoadyuvante
Anatomy::Body Regions::Head::Face::Mouth [Medical Subject Headings]
Chemicals and Drugs::Biological Factors::Biological Markers::Antigens
Differentiation::Antigens
CD::Programmed Cell Death 1 Receptor [Medical Subject Headings]
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [Medical Subject Headings]
Chemicals and Drugs::Amino Acids
Peptides
and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies
Monoclonal [Medical Subject Headings]
Inmunoterapia
Head and neck cancer
Microbiota
Boca
Programmed cell death-1
Organisms::Eukaryota::Plants::Viridiplantae::Streptophyta::Embryophyta::Angiosperms::Solanaceae::Tobacco [Medical Subject Headings]
Phenomena and Processes::Immune System Phenomena::Immunity [Medical Subject Headings]
Prognosis
Muerte celular
Oral cavity
Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Death::Apoptosis [Medical Subject Headings]
Phenomena and Processes::Microbiological Phenomena::Microbiota [Medical Subject Headings]
Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Drinking Behavior::Alcohol Drinking [Medical Subject Headings]
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy::Chemoradiotherapy [Medical Subject Headings]
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Radiotherapy::Radiotherapy
Adjuvant [Medical Subject Headings]
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]
Immunotherapy
Neoadjuvant
Popis: Squamous cell carcinoma of oral cavity (OCSCC) accounts for approximately 25% of cases of head and neck squamous cell carcinoma (HNSCC). Tobacco and alcohol consumption are the main risk factors for both cancers. Surgical resection, combined with adjuvant radiotherapy or radiochemotherapy in patients with high risk of relapse, is the key element in management in the initial stages. However, despite the availability of aggressive multidisciplinary treatments, advanced resectable OCSCC carries poor prognosis; only half of the patients are disease-free 5 years after the surgery. Immunotherapy based on the use of immune checkpoint inhibitors has been proven to be effective in a wide variety of tumours, including recurrent and metastatic HNSCC. These positive results resulted in investigations into its effectiveness in earlier stages of the disease with OCSCC emerging as an interesting research model because of the accessible location of the tumours. This article reviews the potential advantages of emerging immunotherapeutic agents [mainly monoclonal antibodies against programmed cell death-1 (PD-1) immune checkpoint inhibitors] as neoadjuvant treatment for OCSCC at locoregional stages as well as the ongoing clinical trials, challenges in evaluating tumour response, and possible predictive biomarkers of response with highlights regarding the role of oral microbiota as modulators of immune response. The efficacy and safety of anti-PD-1 drugs in these patients have been proven in preliminary trials. If there is a decrease in the relapse rate and an improvement in the overall survival after surgical resection in ongoing trials, preoperative immunotherapy may be established as a treatment option for patients with early stages of the disease. Yes
Databáze: OpenAIRE
Externí odkaz: